GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (OTCPK:HOPHF) » Definitions » Intangible Assets

Hemogenyx Pharmaceuticals (Hemogenyx Pharmaceuticals) Intangible Assets : $0.56 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Hemogenyx Pharmaceuticals Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Hemogenyx Pharmaceuticals's intangible assets for the quarter that ended in Dec. 2023 was $0.56 Mil.


Hemogenyx Pharmaceuticals Intangible Assets Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals Intangible Assets Chart

Hemogenyx Pharmaceuticals Annual Data
Trend Feb15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intangible Assets
Get a 7-Day Free Trial Premium Member Only 0.34 0.34 0.59 0.54 0.56

Hemogenyx Pharmaceuticals Semi-Annual Data
Feb15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.61 0.54 0.56 0.56

Hemogenyx Pharmaceuticals Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Hemogenyx Pharmaceuticals  (OTCPK:HOPHF) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Hemogenyx Pharmaceuticals Intangible Assets Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Hemogenyx Pharmaceuticals (Hemogenyx Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.